Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

MTNB vs OGEN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MTNB Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 4–1 Matrix Metrics)

MTNB Overall Winner 6-Pillar Tally: MTNB 2 – 1 OGEN (3 Tie) Matrix Metrics: MTNB 4 – 1 OGEN

As of Nov 19, 2026, Matinas BioPharma Holdings, Inc. (MTNB) is the stronger overall head-to-head candidate over Oragenics Inc. (OGEN) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). MTNB carries a Unified Composite Score of 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin), whereas OGEN carries 40.8/100 (SELL) at $0.17 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0); meanwhile OGEN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 15.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MTNB vs OGEN
MTNB NYSE American Head-to-Head Winner
Matinas BioPharma Holdings, Inc.
Pharmaceutical Preparations
$0.81
-10.98% 1D
Market Cap $979,904
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -7.20β · 147% Vol
Unified Composite Score
54.6 / 100 HOLD
Tech 53.0 Fund 58.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 33
RSI-14: 33.0 · SMA20: $1.26 · SMA50: $1.47
OGEN NYSE American
Oragenics Inc.
Pharmaceutical Preparations
$0.17
-8.99% 1D
Market Cap $852,759
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.23β · 154% Vol
Unified Composite Score
40.8 / 100 SELL
Tech 30.0 Fund 50.0 Flow 50.0 Mom 75.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.1%), weak momentum, RSI 16
RSI-14: 15.6 · SMA20: $0.32 · SMA50: $0.41

6-Pillar Scorecard Institutional Category Breakdown (MTNB 2 – 1 OGEN)

Columns: Metric · MTNB · OGEN
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale OGEN
Revenue Growth (YoY) -100.0% -91.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $979,904 $852,759
3. Profitability & Quality MTNB
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -147.5% -1307.1%
4. Balance Sheet & Cash Flow MTNB
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.2M Net Cash $1.94 Book/Sh · -1307.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MTNB (4) vs OGEN (1)
Institutional Metric MTNB OGEN Criterion Row Edge
Market Capitalization
Scale
$979,904 $852,759 Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% -91.3% Higher Growth OGEN
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-147.5% -1307.1% Higher ROE MTNB
52-Week Range Position
Momentum
22% ($0–$3) 4% ($0–$1) Stronger Trend MTNB
Beta / 30D Volatility
Risk Regime
-7.20β · 147% Vol 1.23β · 154% Vol Lower Realized Risk MTNB
Unified Institutional Score
Composite Signal
54.6 / 100 (HOLD) 40.8 / 100 (SELL) Higher Composite MTNB
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($1.2M Net Cash) N/A ($1.94 Book/Sh · -1307.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MTNB +11.63 pp
MTNB: -46.7% · OGEN: -58.33%
3M Horizon MTNB +374.73 pp
MTNB: +307.49% · OGEN: -67.24%
6M Horizon MTNB +91.78 pp
MTNB: +20.93% · OGEN: -70.85%
1Y Horizon MTNB +52.76 pp
MTNB: -31.35% · OGEN: -84.11%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MTNB Revenue OGEN Revenue MTNB Op. Margin OGEN Op. Margin Margin Leader
FY2015 $0M N/A -5096.0% N/A MTNB
FY2017 $0M N/A -11024.6% N/A MTNB
FY2018 $0M N/A -12230.9% N/A MTNB
FY2019 $0M N/A -21067.4% N/A MTNB
FY2020 $0M N/A -15288.4% N/A MTNB
FY2021 $0M $0M -74954.5% -18130.3% OGEN
FY2022 $0M $0M -771.3% -10964.6% MTNB
FY2023 $0M $0M -2168.4% -55519.9% MTNB

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MTNB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MTNB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OGEN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MTNB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $979,904 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OGEN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $852,759 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MTNB vs OGEN Key Questions & Quantitative Answers

As of Nov 19, 2026, Matinas BioPharma Holdings, Inc. (MTNB) is the stronger overall head-to-head candidate over Oragenics Inc. (OGEN) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). MTNB carries a Unified Composite Score of 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin), whereas OGEN carries 40.8/100 (SELL) at $0.17 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0); meanwhile OGEN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 15.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OGEN leads the Growth & Scale pillar: MTNB posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with OGEN at -91.3% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2015 to FY2023), MTNB cumulative revenue shifted N/A while OGEN shifted N/A. In operating R&D and SG&A reinvestment, MTNB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OGEN.

MTNB and OGEN trade at balanced relative valuation multiples. MTNB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas OGEN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MTNB (-147.5% ROE) versus OGEN (-1307.1% ROE) capital efficiency.

In options market volatility and institutional positioning, MTNB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.20β · 147% Vol realized risk). By comparison, OGEN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.23β · 154% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.